Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%
- Published
- Source
- YahooFinance
Iovance Biotherapeutics Inc. experienced a significant surge in its stock price, rising by 15.57% to close at $4.38 on Thursday, June 4, 2026, following the conditional approval of its melanoma treatment, Amtagvi, by Australia’s Therapeutic Goods Administration (TGA). This marks the third marketing authorization for Amtagvi, which has already received approvals in the United States and Canada.
The approval is particularly noteworthy as Australia has the highest melanoma incidence rate globally, with approximately 17,000 new cases and over 1,500 related deaths each year. Frederick Vogt, President and CEO of Iovance Biotherapeutics, emphasized the importance of this milestone, stating it represents a significant advancement for the company in a region heavily affected by melanoma.
Iovance is currently in the process of establishing its first treatment center in Australia as part of its strategy to expand Amtagvi into additional markets with high rates of advanced melanoma. The TGA's approval was based on positive safety and efficacy results from the global, multicenter C-144-01 trial, which evaluated Amtagvi in patients with advanced melanoma who had previously undergone anti-PD-1 therapy and, where applicable, targeted therapy.
Original report
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%
YahooFinanceThis briefing is an independently written summary based on publicly available reporting and is provided for industry information and news discovery. The original report and source publication are credited and linked where applicable. RobotToday does not claim ownership of third-party source material.
Rights concerns? Contact [email protected] with the relevant URL and details. We will review the matter and take appropriate action where warranted.
More related news
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
Related Suppliers
Aiyuwencheng 江苏艾雨文承养老机器人有限公司
China
Chinese eldercare robot maker behind 'Datou A Liang', China's first home-based companion robot for seniors with active patrol and sleep monitoring.
Blue Frog Robotics
France
French social robotics company developing Buddy, an emotional AI companion robot for education, eldercare, inclusion, and hospitality.
Bodyfriend 바디프랜드
Korea, Republic of (South)
Seoul-based massage and wellness chair maker founded 2007; builds the Falcon, Familie, and 733 chair lines using its patented ROVO bipedal leg-massage system.
McMaster Manufacturing Research Institute
Canada
Hamilton, Ontario applied manufacturing research center at McMaster University; runs a 21,000 sq ft facility with seven research labs.
Robotics Education & Competition Foundation
United States
The REC Foundation is a US nonprofit that runs VEX-based robotics and drone competitions reaching 1.1 million students across 70 countries.
I Hub Research and Robotics Private Limited (iHub Robotics)
India
Kochi startup (relaunched 2022) making the TARA Gen1 semi-humanoid service robot and Daksha industrial humanoid, exported to the UAE and Saudi Arabia.
Robotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Join the RobotToday community on LinkedIn
Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.
